MarketGrader Europe 100 Index


Five Largest Companies
Symbol Name Grade Market Cap Country
ASML.NL ASML Holding NV 59.3 ¤586,923 NL
RO.CH Roche Holding Ltd 63.9 ¤336,506 CH
HSBA.GB HSBC Holdings Plc 46.2 ¤305,581 GB
AZN.GB AstraZeneca PLC 60.7 ¤283,958 GB
NOVN.CH Novartis AG 50.3 ¤272,264 CH

Five Smallest Companies
Symbol Name Grade Market Cap Country
BOL.SE Boliden AB 62.9 ¤15,594 SE
STMN.CH Straumann Holding AG 52.7 ¤16,996 CH
CARL.B.DK Carlsberg AS Class B 53.2 ¤17,122 DK
MTX.DE MTU Aero Engines AG 73.7 ¤17,147 DE
HAL.NL HAL Trust 63.6 ¤17,468 NL

Companies with Most Selections Among Current Components
Symbol Name Grade Times* Country
ASML.NL ASML Holding NV 59.3 34 NL
ACN Accenture Plc Class A 63.1 33 IE
DNB.NO DNB Bank ASA 51.5 30 NO
ALV.DE Allianz SE 54.4 29 DE
LR.FR Legrand SA 57.5 29 FR
NOVO.B.DK Novo Nordisk A/S Class B 76.8 29 DK
TEL TE Connectivity plc 69.1 27 IE
ETN Eaton Corp. Plc 56.7 26 IE
MUV2.DE Munchener Ruckversicherungs-Gesellschaft 47.4 26 DE
SAND.SE Sandvik AB 52.6 25 SE
*Number of times selected at Index semi-annual reconstitutions since inception date.
Index Bio
Average Market Cap ¤80,835
Median Market Cap ¤47,294
Avg. 3 Mo. Dollar Vol. ¤217,512,249
Avg. 3 Mo. Trading Vol. 4,386,786
Last Rebalance Date 03/23/2026
Companies Replaced 38
Biggest Sector Increase Industrials
Biggest Sector Decrease Health Care

Fundamental Attributes
Trailing P/E Ratio (12 Mo.) 16.6
Forward P/E Ratio (12 Mo.) 14.4
Price/Book Ratio 3.6
Avg. Revenue Chg. - 3 Yr 22.7%
Avg. Op. Income Chg. - 3 Yr. 44.8%
Avg. EPS Growth - 3 Yr. 15.5%
Avg. EPS Growth - 1 Yr. 15.8%
Avg. Operating Margin 19.7%
Avg. LT Debt to Total Capital 41.7%
Avg. Return on Equity 18.3%
Dividend Yield 2.1%
Index Average Grade
Europe 100 Index 57.9
Country Breakdown
United Kingdom 20.0%
Ireland 12.0%
Switzerland 11.0%
Germany 11.0%
Italy 8.0%
France 8.0%
Netherlands 8.0%
Sweden 8.0%
Spain 4.0%
Denmark 3.0%
Finland 2.0%
Luxembourg 2.0%
Austria 2.0%
Norway 1.0%
For more information on this index please contact us

Get Access to the World's Smartest Global Research Platform

Don't wait another day to make better informed, higher-returning investments.

TRY IT FOR FREE